Compare HAVA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAVA | GALT |
|---|---|---|
| Founded | 2024 | 2000 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.9M | 176.7M |
| IPO Year | N/A | 2008 |
| Metric | HAVA | GALT |
|---|---|---|
| Price | $9.99 | $3.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 144.0K | ★ 242.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $1.15 |
| 52 Week High | $10.01 | $7.13 |
| Indicator | HAVA | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 51.18 |
| Support Level | $9.94 | $2.90 |
| Resistance Level | $10.01 | $3.27 |
| Average True Range (ATR) | 0.01 | 0.19 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 49.75 | 73.57 |
Harvard Ave Acquisition Corp is a blank check company.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.